dermatomyositis

Summary

Summary: A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6)

Top Publications

  1. Bader Meunier B, Monnet D, Barnerias C, Halphen I, Lambot Juhan K, Chalumeau M, et al. Thrombotic microangiopathy and Purtscher-like retinopathy as a rare presentation of juvenile dermatomyositis. Pediatrics. 2012;129:e821-4 pubmed publisher
    Juvenile dermatomyositis is a rare systemic vasculopathy that may sometimes present with acute complications. We report here the case of a 7-year-old boy with severe dermatomyositis associated with thrombocytopenia and blurry vision...
  2. Chandiramani M, Joynson C, Panchal R, Symonds R, Brown L, Morgan B, et al. Dermatomyositis as a paraneoplastic syndrome in carcinosarcoma of uterine origin. Clin Oncol (R Coll Radiol). 2006;18:641-8 pubmed
    ..b>Dermatomyositis can occur in association with malignancy as a paraneoplastic phenomenon...
  3. Nabatian A, Bashir M, Wysocka M, Sharma M, Werth V. Tumor necrosis factor ? release in peripheral blood mononuclear cells of cutaneous lupus and dermatomyositis patients. Arthritis Res Ther. 2012;14:R1 pubmed publisher
    ..lesions of patients with discoid lupus erythematosus (DLE), subacute cutaneous lupus erythematosus (SCLE) and dermatomyositis (DM) compared to controls...
  4. Baek A, Park H, Na S, Shim D, Moon J, Yang Y, et al. The expression of BAFF in the muscles of patients with dermatomyositis. J Neuroimmunol. 2012;249:96-100 pubmed publisher
    ..b>Dermatomyositis (DM), one of autoimmune inflammatory myopathies, is characterized by inflammatory cell infiltration (CD4(+) T ..
  5. Arai S, Kurasawa K, Maezawa R, Owada T, Okada H, Fukuda T. Marked increase in serum KL-6 and surfactant protein D levels during the first 4 weeks after treatment predicts poor prognosis in patients with active interstitial pneumonia associated with polymyositis/dermatomyositis. Mod Rheumatol. 2013;23:872-83 pubmed publisher
    ..levels predict the prognosis of patients with interstitial pneumonia (IP) in cases of polymyositis (PM) and dermatomyositis (DM)...
  6. Fujimoto M, Hamaguchi Y, Kaji K, Matsushita T, Ichimura Y, Kodera M, et al. Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins. Arthritis Rheum. 2012;64:513-22 pubmed publisher
    ..140-kd autoantigen recognized by anti-155/140 autoantibodies that are associated with adult cancer-associated dermatomyositis (DM) and juvenile DM and to determine the clinical relevance of anti-155/140 antibodies in a large cohort...
  7. Gherardi R. Pathogenic aspects of dermatomyositis, polymyositis and overlap myositis. Presse Med. 2011;40:e209-18 pubmed publisher
    ..have distinct histopathologic features suggesting humorally mediated involvement of the microcirculation in dermatomyositis (DM), including early capillary deposition of the complement C5b-9 membranolytic attack complex (MAC) and ..
  8. Niewold T, Wu S, Smith M, Morgan G, Pachman L. Familial aggregation of autoimmune disease in juvenile dermatomyositis. Pediatrics. 2011;127:e1239-46 pubmed publisher
    ..Familial aggregation of autoimmunity has not been examined in juvenile dermatomyositis. Interferon-? is thought to be a pathogenic factor in both systemic lupus erythematosus and juvenile ..
  9. Samuels N, Applbaum Y, Esayag Y. Paraneoplastic necrotizing myopathy and dermatomyositis in a patient with rectosigmoid carcinoma. Rheumatol Int. 2013;33:1619-21 pubmed publisher
    ..Four months later she returned with exacerbation of symptoms, this time with skin changes pathognomonic of dermatomyositis (DM). A repeat MRI showed progression of inflammation, as well as necrotic foci...

More Information

Publications82

  1. Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol. 2011;147:391-8 pubmed publisher
    To clarify the association of clinical and prognostic features with dermatomyositis (DM)-specific autoantibodies (Abs) in adult Japanese patients with DM. Retrospective study...
  2. Kim J, Werth V. Identification of specific chondroitin sulfate species in cutaneous autoimmune disease. J Histochem Cytochem. 2011;59:780-90 pubmed publisher
    Cutaneous lupus erythematosus and dermatomyositis (DM) are chronic inflammatory diseases of the skin with accumulated dermal mucin...
  3. Muro Y, Sugiura K, Hoshino K, Akiyama M. Disappearance of anti-MDA-5 autoantibodies in clinically amyopathic DM/interstitial lung disease during disease remission. Rheumatology (Oxford). 2012;51:800-4 pubmed publisher
    ..Serial monitoring at short intervals is required to evaluate whether anti-MDA-5 antibody levels correlate with ADM disease activity. ..
  4. Robinson A, Thierry Palmer M, Gibson K, Rabinovich C. Disease activity, proteinuria, and vitamin D status in children with systemic lupus erythematosus and juvenile dermatomyositis. J Pediatr. 2012;160:297-302 pubmed publisher
    To evaluate relationships among vitamin D, proteinuria, and disease activity in pediatric systemic lupus erythematosus (SLE) and juvenile dermatomyositis (JDM).
  5. Cappelletti C, Baggi F, Zolezzi F, Biancolini D, Beretta O, Severa M, et al. Type I interferon and Toll-like receptor expression characterizes inflammatory myopathies. Neurology. 2011;76:2079-88 pubmed publisher
    Juvenile dermatomyositis (JDM), adult dermatomyositis, and polymyositis (PM) are idiopathic inflammatory myopathies (IIMs) characterized by muscle infiltration and specific muscle fiber alterations...
  6. Wu H, Geng D, Xu J. An approach to the development of interstitial lung disease in dermatomyositis: a study of 230 cases in China. J Int Med Res. 2013;41:493-501 pubmed publisher
    To study the clinical features of interstitial lung disease (ILD) in patients with dermatomyositis and factors related to its development. : Clinical records for patients with dermatomyositis were reviewed retrospectively...
  7. Muro Y, Sugiura K, Akiyama M. Low prevalence of anti-small ubiquitin-like modifier activating enzyme antibodies in dermatomyositis patients. Autoimmunity. 2013;46:279-84 pubmed publisher
    ..autoantibodies that characterize certain forms of inflammatory myopathy are useful in diagnosing dermatomyositis (DM) / polymyositis and predicting its prognosis...
  8. Butbul Aviel Y, Stremler R, Benseler S, Cameron B, Laxer R, Ota S, et al. Sleep and fatigue and the relationship to pain, disease activity and quality of life in juvenile idiopathic arthritis and juvenile dermatomyositis. Rheumatology (Oxford). 2011;50:2051-60 pubmed publisher
    ..Strategies aimed at improving sleep and reducing fatigue should be studied as possible ways of improving quality of life for children with rheumatic illness. ..
  9. Muro Y, Sugiura K, Hoshino K, Akiyama M, Tamakoshi K. Epidemiologic study of clinically amyopathic dermatomyositis and anti-melanoma differentiation-associated gene 5 antibodies in central Japan. Arthritis Res Ther. 2011;13:R214 pubmed publisher
    ..autoantibodies against melanoma differentiation-associated gene 5 (MDA-5) in more than 20% of patients with dermatomyositis. Anti-MDA-5 antibodies were associated with the presence of rapidly progressive interstitial lung disease in ..
  10. Robinson A, Reed A. Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis. Nat Rev Rheumatol. 2011;7:664-75 pubmed publisher
    Juvenile and adult dermatomyositis (DM) have multiple commonalities, yet display differing prevalence of features, outcomes and comorbidities...
  11. Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford). 2012;51:1563-70 pubmed publisher
    ..Anti-MDA5ab titre and ferritin and IL-18 concentrations are useful for the evaluation of the response to treatment and the status of ILD in patients with anti-MAD5ab-positive DM. ..
  12. Guseinova D, Consolaro A, Trail L, Ferrari C, Pistorio A, Ruperto N, et al. Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis. Clin Exp Rheumatol. 2011;29:117-24 pubmed
    To compare the demographic features, presenting manifestations, diagnostic investigations, disease course, and drug therapies of children with juvenile dermatomyositis (JDM) followed in Europe and Latin America.
  13. Morita Y, Kuwagata S, Kato N, Tsujimura Y, Mizutani H, Suehiro M, et al. 18F-FDG PET/CT useful for the early detection of rapidly progressive fatal interstitial lung disease in dermatomyositis. Intern Med. 2012;51:1613-8 pubmed
    Interstitial lung disease (ILD) frequently accompanies polymyositis (PM) and dermatomyositis (DM) and is a major cause of mortality. The rapid diagnosis of ILD is paramount...
  14. Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Watanabe K, et al. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med. 2011;105:1380-7 pubmed publisher
    ..antibody, is a myositis-specific antibody identified in the sera of patients with clinically amyopathic dermatomyositis (C-ADM) and is associated with a worse prognosis in dermatomyositis-associated interstitial lung disease (DM-..
  15. Dourmishev L, Kamenarska Z, Hristova M, Dodova R, Kaneva R, Mitev V. Association of TNF-? polymorphisms with adult dermatomyositis and systemic lupus erythematosus in Bulgarian patients. Int J Dermatol. 2012;51:1467-73 pubmed publisher
    ..This is a pilot study to investigate the association of six SNPs of the TNF-? gene with the risk of adult dermatomyositis (DM) and systemic lupus erythematosus (SLE) in Bulgarian patients.
  16. Venalis P, Lundberg I. Immune mechanisms in polymyositis and dermatomyositis and potential targets for therapy. Rheumatology (Oxford). 2014;53:397-405 pubmed publisher
    ..Such information will be important for the development of new therapies. ..
  17. Tollisen A, Sanner H, Flatø B, Wahl A. Quality of life in adults with juvenile-onset dermatomyositis: a case-control study. Arthritis Care Res (Hoboken). 2012;64:1020-7 pubmed publisher
    To compare quality of life in adults diagnosed with juvenile dermatomyositis (DM) with that of matched controls, and to analyze the association with other disease parameters in patients.
  18. Kim N, Lio P, Morgan G, Jarvis J, Pachman L. Double trouble: therapeutic challenges in patients with both juvenile dermatomyositis and psoriasis. Arch Dermatol. 2011;147:831-5 pubmed publisher
    Juvenile dermatomyositis (JDM) and psoriasis are inflammatory disorders that share interferon-? induced responses and dysregulation of cytokines, including tumor necrosis factor alpha...
  19. Sugie K, Tonomura Y, Ueno S. Characterization of dermatomyositis with coexistence of anti-Jo-1 and anti-SRP antibodies. Intern Med. 2012;51:799-802 pubmed
    We describe a patient with dermatomyositis who presented with rapidly developing severe muscle weakness complicated by massive pleural effusion with interstitial lung disease. Myopathological analysis was suggestive of dermatomyositis...
  20. Khan S, Christopher Stine L. Polymyositis, dermatomyositis, and autoimmune necrotizing myopathy: clinical features. Rheum Dis Clin North Am. 2011;37:143-58, v pubmed publisher
    ..The 3 most common inflammatory myopathies are polymyositis (PM), dermatomyositis (DM), and inclusion body myositis...
  21. Baechler E, Bilgic H, Reed A. Type I interferon pathway in adult and juvenile dermatomyositis. Arthritis Res Ther. 2011;13:249 pubmed publisher
    ..the type I interferon pathway have revealed important insights into the disease process in adult and juvenile dermatomyositis. The most prominent and consistent feature has been a characteristic whole blood gene signature indicating ..
  22. Ernste F, Crowson C, de Padilla C, Hein M, Reed A. Longitudinal peripheral blood lymphocyte subsets correlate with decreased disease activity in juvenile dermatomyositis. J Rheumatol. 2013;40:1200-11 pubmed publisher
    To determine the clinical characteristics and subsets of peripheral blood lymphocytes (PBL), which correlate with decreased disease activity in patients with juvenile dermatomyositis (JDM).
  23. Hall J, Casciola Rosen L, Samedy L, Werner J, Owoyemi K, Danoff S, et al. Anti-melanoma differentiation-associated protein 5-associated dermatomyositis: expanding the clinical spectrum. Arthritis Care Res (Hoboken). 2013;65:1307-15 pubmed publisher
    ..against melanoma differentiation-associated protein 5 (MDA-5) have been described in several Asian dermatomyositis (DM) cohorts, often associated with amyopathic DM and rapidly progressive interstitial lung disease (ILD)...
  24. Habers E, van Brussel M, Langbroek Amersfoort A, van Royen Kerkhof A, Takken T. Design of the muscles in motion study: a randomized controlled trial to evaluate the efficacy and feasibility of an individually tailored home-based exercise training program for children and adolescents with juvenile dermatomyositis. BMC Musculoskelet Disord. 2012;13:108 pubmed publisher
    Juvenile dermatomyositis (JDM) is a rare, often chronic, systemic autoimmune disease of childhood, characterized by inflammation of the microvasculature of the skeletal muscle and skin...
  25. Marie I, Hatron P, Dominique S, Cherin P, Mouthon L, Menard J. Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum. 2011;63:3439-47 pubmed publisher
    This study was undertaken to assess the characteristics and outcome of interstitial lung disease (ILD) in polymyositis/dermatomyositis (PM/DM) and to determine variables predictive of ILD deterioration in PM/DM.
  26. Owada T, Maezawa R, Kurasawa K, Okada H, Arai S, Fukuda T. Detection of inflammatory lesions by f-18 fluorodeoxyglucose positron emission tomography in patients with polymyositis and dermatomyositis. J Rheumatol. 2012;39:1659-65 pubmed publisher
    ..We examined whether FDG-PET scanning detects myositis or extramuscular lesions in patients with polymyositis (PM) and dermatomyositis (DM).
  27. Greenberg S, Higgs B, Morehouse C, Walsh R, Kong S, Brohawn P, et al. Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis. Genes Immun. 2012;13:207-13 pubmed publisher
    ..between blood mRNA, disease activity and treatment effects in a longitudinal study of patients with dermatomyositis (DM) or polymyositis (PM). In all, 24 patients with DM or PM were followed for up to 6 years (mean of 1...
  28. Uchino M, Yamashita S, Uchino K, Mori A, Hara A, Suga T, et al. Muscle biopsy findings predictive of malignancy in rare infiltrative dermatomyositis. Clin Neurol Neurosurg. 2013;115:603-6 pubmed publisher
    The characteristic pathological muscular findings of polymyositis (PM) and dermatomyositis (DM) have been shown to reflect their different pathogeneses...
  29. Gendek Kubiak H, Gendek E. Fascin-expressing dendritic cells dominate in polymyositis and dermatomyositis. J Rheumatol. 2013;40:186-91 pubmed publisher
  30. Labirua Iturburu A, Selva O Callaghan A, Vincze M, Danko K, Vencovsky J, Fisher B, et al. Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. Medicine (Baltimore). 2012;91:206-11 pubmed publisher
    ..8-10.7 yr), and 4 patients died. All patients had myositis (12 polymyositis, 5 dermatomyositis, and 1 amyopathic dermatomyositis), 10 (55...
  31. Hristova M, Dourmishev L, Kamenarska Z, Kaneva R, Vinkov A, Mitev V. Association of tumor necrosis factor ? (TNF-?) and interleukin 10 (IL-10) gene polymorphisms in dermatomyositis patients: a pilot study. Acta Dermatovenerol Croat. 2012;20:148-56 pubmed
    ..case-control study aimed to investigate the association between six TNF-? and five IL-10 polymorphisms with dermatomyositis. The -857CC and +489GG genotypes showed a weak association with dermatomyositis when the analysis was carried ..
  32. Balboni I, Niewold T, Morgan G, Limb C, Eloranta M, Rönnblom L, et al. Interferon-? induction and detection of anti-ro, anti-la, anti-sm, and anti-rnp autoantibodies by autoantigen microarray analysis in juvenile dermatomyositis. Arthritis Rheum. 2013;65:2424-9 pubmed publisher
    To evaluate serum interferon-? (IFN?) activity in the context of autoantibody profiles in patients with juvenile dermatomyositis (JDM).
  33. Marie I. Morbidity and mortality in adult polymyositis and dermatomyositis. Curr Rheumatol Rep. 2012;14:275-85 pubmed publisher
    Before the use of corticosteroids, the prognosis for polymyositis/dermatomyositis (PM/DM) was extremely poor...
  34. Aikawa N, Jesus A, Liphaus B, Silva C, Carneiro Sampaio M, Viana V, et al. Organ-specific autoantibodies and autoimmune diseases in juvenile systemic lupus erythematosus and juvenile dermatomyositis patients. Clin Exp Rheumatol. 2012;30:126-31 pubmed
    ..prevalence of organ-specific autoimmune diseases in juvenile systemic lupus erythematosus (JSLE) and juvenile dermatomyositis (JDM)...
  35. Fujita Y, Hirano S, Yoneshim Y, Izumi S, Takeda Y, Sugiyama H, et al. [A case of acute exacerbation of interstitial pneumonia complicated with dermatomyositis during treatment for lung cancer, and literature review]. Nihon Kokyuki Gakkai Zasshi. 2011;49:108-15 pubmed
    ..Based on clinical and histopathological examinations, the patient was given a diagnosis of dermatomyositis. He was treated with chemotherapy (carboplatin/paclitaxel) for lung cancer and his dermatomyositis was ..
  36. Zong M, Loell I, Lindroos E, Nader G, Alexanderson H, Hallengren C, et al. Effects of immunosuppressive treatment on interleukin-15 and interleukin-15 receptor ? expression in muscle tissue of patients with polymyositis or dermatomyositis. Ann Rheum Dis. 2012;71:1055-63 pubmed publisher
    To investigate the expression of interleukin (IL)-15 and IL-15 receptor ? (IL-15R?) in muscle tissue from patients with polymyositis or dermatomyositis before and after conventional immunosuppressive (IS) treatment.
  37. Wang H, Tang J, Chen X, Li F, Luo J. Lipid profiles in untreated patients with dermatomyositis. J Eur Acad Dermatol Venereol. 2013;27:175-9 pubmed publisher
    ..However, serum lipid profiles in patients with dermatomyositis (DM) have not been investigated...
  38. Eimer M, Brickman W, Seshadri R, Ramsey Goldman R, McPherson D, Smulevitz B, et al. Clinical status and cardiovascular risk profile of adults with a history of juvenile dermatomyositis. J Pediatr. 2011;159:795-801 pubmed publisher
    A pilot study of adults who had onset of juvenile dermatomyositis (JDM) in childhood, before current therapeutic approaches, to characterize JDM symptoms and subclinical cardiovascular disease.
  39. Sato S, Kuwana M, Fujita T, Suzuki Y. Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies. Mod Rheumatol. 2012;22:625-9 pubmed publisher
    Anti-clinically amyopathic dermatomyositis (CADM)-140/MDA5 autoantibodies are specifically detected in patients with dermatomyositis and are known to have a strong association with rapidly progressive interstitial lung disease (RP-ILD)...
  40. Trallero Araguas E, Rodrigo Pendás J, Selva O Callaghan A, Martínez Gómez X, Bosch X, Labrador Horrillo M, et al. Usefulness of anti-p155 autoantibody for diagnosing cancer-associated dermatomyositis: a systematic review and meta-analysis. Arthritis Rheum. 2012;64:523-32 pubmed publisher
    Anti-p155 autoantibody, which was recently described in adult patients with dermatomyositis (DM), seems to be associated with cancer in this population...
  41. Mathiesen P, Hegaard H, Herlin T, Zak M, Pedersen F, Nielsen S. Long-term outcome in patients with juvenile dermatomyositis: a cross-sectional follow-up study. Scand J Rheumatol. 2012;41:50-8 pubmed publisher
    To evaluate a group of 53 patients with juvenile dermatomyositis (JDM), on average 13...
  42. Labrador Horrillo M, Martínez M, Selva O Callaghan A, Trallero Araguas E, Balada E, Vilardell Tarres M, et al. Anti-TIF1? antibodies (anti-p155) in adult patients with dermatomyositis: comparison of different diagnostic assays. Ann Rheum Dis. 2012;71:993-6 pubmed publisher
    ..A new myositis-specific autoantibody (anti-p155) directed against transcriptional intermediary factor 1 ? (TIF1?) has been described as a good marker of cancer-associated myositis (CAM)...
  43. Yamasaki Y, Yamada H, Ohkubo M, Yamasaki M, Azuma K, Ogawa H, et al. Longterm survival and associated risk factors in patients with adult-onset idiopathic inflammatory myopathies and amyopathic dermatomyositis: experience in a single institute in Japan. J Rheumatol. 2011;38:1636-43 pubmed publisher
    ..To analyze clinical characteristics, survival, causes of death, and risk factors associated with mortality in patients with adult-onset idiopathic inflammatory myopathies (IIM) in Japan...
  44. Wang D, Zhang H, Cao M, Tang Y, Liang J, Feng X, et al. Efficacy of allogeneic mesenchymal stem cell transplantation in patients with drug-resistant polymyositis and dermatomyositis. Ann Rheum Dis. 2011;70:1285-8 pubmed publisher
    To assess the safety and clinical efficacy of allogeneic mesenchymal stem cell transplantation (MSCT) in a small-scale pilot study with 10 patients with drug-resistant polymyositis (PM) or dermatomyositis (DM).
  45. Yuan L, Yao L, Zhao L, Xia L, Shen H, Lu J. Serum levels of soluble ST2 and interleukin-33 in patients with dermatomyositis and polymyositis. Clin Exp Rheumatol. 2013;31:428-32 pubmed
    The purpose of this study is to determine whether soluble ST2 (sST2) and interleukin (IL)-33 is involved in dermatomyositis (DM) and polymyositis (PM).
  46. Ladd P, Emery K, Salisbury S, Laor T, Lovell D, Bove K. Juvenile dermatomyositis: correlation of MRI at presentation with clinical outcome. AJR Am J Roentgenol. 2011;197:W153-8 pubmed publisher
    The clinical course of juvenile dermatomyositis (JDMS) is unpredictable. MRI is used to determine muscle biopsy site and to monitor disease activity...
  47. Oddis C, Reed A, Aggarwal R, Rider L, Ascherman D, Levesque M, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65:314-24 pubmed publisher
    ..To assess the safety and efficacy of rituximab in a randomized, double-blind, placebo-phase trial in adult and pediatric myositis patients...
  48. Oshikawa Y, Jinnin M, Makino T, Kajihara I, Makino K, Honda N, et al. Decreased miR-7 expression in the skin and sera of patients with dermatomyositis. Acta Derm Venereol. 2013;93:273-6 pubmed publisher
    Expression of microRNA (miRNA) in the skin in dermatomyositis has not previously been studied in detail...
  49. Kim E, Cook Mills J, Morgan G, Sredni S, Pachman L. Increased expression of vascular cell adhesion molecule 1 in muscle biopsy samples from juvenile dermatomyositis patients with short duration of untreated disease is regulated by miR-126. Arthritis Rheum. 2012;64:3809-17 pubmed publisher
    ..molecule 1 (VCAM-1) and microRNA (miRNA) expression in muscle biopsy samples from children with juvenile dermatomyositis (DM) as well as its effect on soluble VCAM-1 (sVCAM-1) and tumor necrosis factor ? (TNF?) concentrations in ..
  50. Sato S, Kuwana M, Fujita T, Suzuki Y. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol. 2013;23:496-502 pubmed publisher
    ..We examined the relationship between disease activity and anti-CADM-140/MDA5 titer measured by enzyme-linked immunosorbent assay (ELISA)...
  51. Ogata A, Endo M, Aoi J, Takahashi O, Kadomatsu T, Miyata K, et al. The role of angiopoietin-like protein 2 in pathogenesis of dermatomyositis. Biochem Biophys Res Commun. 2012;418:494-9 pubmed publisher
    b>Dermatomyositis (DM) is an autoimmune disease marked by chronic inflammation of skin and muscle tissues and characterized clinically by proximal muscle weakness and skin eruption, including heliotrope rash, and Gottron's sign...
  52. Sugiura T, Kawaguchi Y, Goto K, Hayashi Y, Tsuburaya R, Furuya T, et al. Positive association between STAT4 polymorphisms and polymyositis/dermatomyositis in a Japanese population. Ann Rheum Dis. 2012;71:1646-50 pubmed publisher
    ..transducer and activator of transcription 4 (STAT4), one of the most commonly acknowledged genes for the risk of multiple autoimmune diseases, with susceptibility to adult-onset polymyositis/dermatomyositis among Japanese individuals.
  53. Cao H, Pan M, Kang Y, Xia Q, Li X, Zhao X, et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma differentiation-associated gene 5 antibody. Arthritis Care Res (Hoboken). 2012;64:1602-10 pubmed publisher
    To investigate the clinical features of dermatomyositis (DM) and clinically amyopathic DM (CADM) patients with the presence of anti-melanoma differentiation-associated gene 5 (anti-MDA-5) antibodies.
  54. Marie I, Mouthon L. Therapy of polymyositis and dermatomyositis. Autoimmun Rev. 2011;11:6-13 pubmed publisher
    Because polymyositis and dermatomyositis (PM/DM) are uncommon conditions, few randomized placebo controlled studies have been performed in these patients...
  55. Tansley S, Betteridge Z, McHugh N. The diagnostic utility of autoantibodies in adult and juvenile myositis. Curr Opin Rheumatol. 2013;25:772-7 pubmed publisher
    The purpose of this study is to review recent advances in the diagnostic utility of autoantibodies in dermatomyositis.
  56. Miller F, Cooper R, Vencovský J, Rider L, Danko K, Wedderburn L, et al. Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders. Arthritis Rheum. 2013;65:3239-47 pubmed publisher
    To identify new genetic associations with juvenile and adult dermatomyositis (DM). We performed a genome-wide association study (GWAS) of adult and juvenile DM patients of European ancestry (n = 1,178) and controls (n = 4,724)...
  57. Chang L, Maheshwari P, Werth S, Schaffer L, Head S, Kovarik C, et al. Identification and molecular analysis of glycosaminoglycans in cutaneous lupus erythematosus and dermatomyositis. J Histochem Cytochem. 2011;59:336-45 pubmed publisher
    ..HA) and chondroitin sulfate (CS), using specific stains in cutaneous lupus erythematosus (CLE) and dermatomyositis (DM)...
  58. Wong D, Kea B, Pesich R, Higgs B, Zhu W, Brown P, et al. Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PLoS ONE. 2012;7:e29161 pubmed publisher
    b>Dermatomyositis (DM) is an autoimmune disease that mainly affects the skin, muscle, and lung. The pathogenesis of skin inflammation in DM is not well understood.
  59. Ishikawa A, Muro Y, Sugiura K, Akiyama M. Development of an ELISA for detection of autoantibodies to nuclear matrix protein 2. Rheumatology (Oxford). 2012;51:1181-7 pubmed publisher
    ..This study aimed to identify a subset of DM patients who have anti-nuclear matrix protein 2 (anti-NXP-2) antibodies by using biotinylated recombinant proteins, and to clarify the clinical features of DM patients with these antibodies...
  60. Chen F, Wang D, Shu X, Nakashima R, Wang G. Anti-MDA5 antibody is associated with A/SIP and decreased T cells in peripheral blood and predicts poor prognosis of ILD in Chinese patients with dermatomyositis. Rheumatol Int. 2012;32:3909-15 pubmed publisher
    ..gene 5 prevalence and their clinical associations in Chinese patients with polymyositis and dermatomyositis (PM/DM). Serum anti-MDA5 antibody was detected by ELISA in 113 adult PM/DM patients and in various controls...
  61. Muro Y, Sugiura K, Akiyama M. Limitations of a single-point evaluation of anti-MDA5 antibody, ferritin, and IL-18 in predicting the prognosis of interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Clin Rheumatol. 2013;32:395-8 pubmed publisher
    Autoantibodies against melanoma differentiation-associated gene 5 (MDA5) are important serological markers in dermatomyositis (DM) with rapidly progressive interstitial lung disease (ILD)...
  62. Ceribelli A, Fredi M, Taraborelli M, Cavazzana I, Franceschini F, Quinzanini M, et al. Anti-MJ/NXP-2 autoantibody specificity in a cohort of adult Italian patients with polymyositis/dermatomyositis. Arthritis Res Ther. 2012;14:R97 pubmed publisher
    Autoantibodies in patients with polymyositis/dermatomyositis (PM/DM) are associated with unique subsets, clinical course and outcome...
  63. Ikeda N, Takahashi K, Yamaguchi Y, Inasaka M, Kuwana M, Ikezawa Z. Analysis of dermatomyositis-specific autoantibodies and clinical characteristics in Japanese patients. J Dermatol. 2011;38:973-9 pubmed publisher
    b>Dermatomyositis (DM) is an idiopathic systemic inflammatory disease that is often accompanied by interstitial lung disease (ILD) or internal malignancy...
  64. Davis W, Halls J, Offiah A, Pilkington C, Owens C, Rosendahl K. Assessment of active inflammation in juvenile dermatomyositis: a novel magnetic resonance imaging-based scoring system. Rheumatology (Oxford). 2011;50:2237-44 pubmed publisher
    ..This system defines markers of inflammatory change in four muscle groups and the surrounding soft tissues...
  65. Hak A, De Paepe B, De Bleecker J, Tak P, de Visser M. Dermatomyositis and polymyositis: new treatment targets on the horizon. Neth J Med. 2011;69:410-21 pubmed
    Polymyositis (PM) and dermatomyositis (DM) are rare idiopathic inflammatory myopathies (IIM) with a presumed autoimmune pathogenesis...
  66. Goreshi R, Chock M, Foering K, Feng R, Okawa J, Rose M, et al. Quality of life in dermatomyositis. J Am Acad Dermatol. 2011;65:1107-16 pubmed publisher
    Quality of life (QoL) for patients with inflammatory skin disease can be significant, but has been evaluated in just one study in dermatomyositis (DM).
  67. Charles Schoeman C, Verity M. Nicotinamide adenine dinucleotide tetrazolium reductase identifies microvasculature activation in muscle from adult patients with dermatomyositis. J Rheumatol. 2012;39:94-9 pubmed publisher
    Previous work has suggested involvement of the muscle microvasculature in the pathogenesis of dermatomyositis (DM)...
  68. So M, Koo B, Kim Y, Lee C, Yoo B. Idiopathic inflammatory myopathy associated with malignancy: a retrospective cohort of 151 Korean patients with dermatomyositis and polymyositis. J Rheumatol. 2011;38:2432-5 pubmed publisher
    To define the standardized incidence ratio (SIR) of malignancy and factors associated with malignancies in Korean patients with dermatomyositis (DM) and polymyositis (PM).
  69. Yu K, Wu Y, Kuo C, See L, Shen Y, Chang H, et al. Survival analysis of patients with dermatomyositis and polymyositis: analysis of 192 Chinese cases. Clin Rheumatol. 2011;30:1595-601 pubmed publisher
    To estimate the mortality rate and identify factors predicting survival in patients with polymyositis (PM) and dermatomyositis (DM)...
  70. Reed A, Peterson E, Bilgic H, Ytterberg S, Amin S, Hein M, et al. Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course. Arthritis Rheum. 2012;64:4078-86 pubmed publisher
    Muscle enzyme levels are insensitive markers of disease activity in juvenile and adult dermatomyositis (DM), especially during the active treatment phase...
  71. Martin N, Krol P, Smith S, Beard L, Pilkington C, Davidson J, et al. Comparison of children with onset of juvenile dermatomyositis symptoms before or after their fifth birthday in a UK and Ireland juvenile dermatomyositis cohort study. Arthritis Care Res (Hoboken). 2012;64:1665-72 pubmed publisher
    To compare 2 groups of children with juvenile dermatomyositis (DM), those with onset of symptoms before their fifth birthday versus those whose disease begins either on or after their fifth birthday, and to assess whether age at onset is ..
  72. Lazarevic D, Pistorio A, Palmisani E, Miettunen P, Ravelli A, Pilkington C, et al. The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis. Ann Rheum Dis. 2013;72:686-93 pubmed publisher
    To develop data-driven criteria for clinically inactive disease on and off therapy for juvenile dermatomyositis (JDM).
  73. de Souza F, Shinjo S. Newly diagnosed dermatomyositis in the elderly as predictor of malignancy. Rev Bras Reumatol. 2012;52:713-21 pubmed
    b>Dermatomyositis (DM) symptoms may be a clue to the existence of a hidden cancer. Enhancing early detection is essential, but there are no studies evaluating short-term predictive factors in this disease.